metformin extended-release tablets (Glumetza™)

 FDA Approved Indication(s):

  • Metformin ER (Glumetza) is indicated for the treatment of type 2 diabetes as monotherapy (in adjunct to diet and exercise) and in combination with insulin or a sulfonylurea. It is indicated in patients ≥ 18 years of age

All of the following must be met as a condition(s) for coverage:

  • Medication is being used for an FDA approved indication

  • Documentation that generic metformin ER (Glucophage equivalent) as well as metformin ER (osmotic) (Fortamet equivalent) were ineffective or not tolerated as validated from prescription claims history and medical record documentation. Medical record documentation must include the trial and intolerance of the metformin ER (Glucophage equivalent) and metformin ER (osmotic) products and must be included with the prior authorization request


  • Authorization for 1 year if approved
  • Renewal must include medical record documentation supporting the need for continued therapy (e.g., solution)


Last review date: July 25, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar